- Home
- UPWK vs CDTX Comparison
UPWK vs CDTX Comparison
Compare UPWK & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UPWK | CDTX |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.8B |
| IPO Year | 2018 | 2015 |
Fundamental Metrics
Financial Performance| Metric | UPWK | CDTX |
|---|---|---|
| Price | $21.98 | $220.54 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 12 |
| Target Price | $21.85 | ★ $128.75 |
| AVG Volume (30 Days) | ★ 5.2M | 2.3M |
| Earning Date | 11-03-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 179.51 | N/A |
| EPS | ★ 1.74 | N/A |
| Revenue | ★ $780,858,000.00 | N/A |
| Revenue This Year | $4.30 | N/A |
| Revenue Next Year | $6.25 | N/A |
| P/E Ratio | $12.64 | ★ N/A |
| Revenue Growth | ★ 2.50 | N/A |
| 52 Week Low | $11.13 | $15.22 |
| 52 Week High | $22.32 | $221.20 |
Technical Indicators
Market Signals| Indicator | UPWK | CDTX |
|---|---|---|
| Relative Strength Index (RSI) | 67.31 | 86.62 |
| Support Level | $19.20 | $219.60 |
| Resistance Level | $21.38 | $220.38 |
| Average True Range (ATR) | 0.93 | 0.74 |
| MACD | 0.21 | -3.92 |
| Stochastic Oscillator | 90.62 | 67.82 |
Price Performance
Historical ComparisonAbout UPWK Upwork Inc.
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with skilled independent professionals. The company develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to clients.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.